Literature DB >> 7954815

Novel infectious particles generated by expression of the vesicular stomatitis virus glycoprotein from a self-replicating RNA.

M M Rolls1, P Webster, N H Balba, J K Rose.   

Abstract

Self-propagating infectious particles were produced in animal cells transfected with an RNA replicon encoding a single viral structural protein, the vesicular stomatitis virus glycoprotein (VSV-G). The replicon is derived from an alphavirus, Semliki Forest virus (SFV), and encodes the SFV RNA replicase, but none of the SFV structural proteins. After transfection of the replicon into tissue culture cells, expression of G protein spread from small foci throughout the culture. Supernatants from the cells contained infectious, virus-like particles that could be passaged and were neutralized by anti-VSV serum. The majority of the infectious particles were smaller and less dense than either VSV or SFV. Characterization by electron microscopy showed membrane-enveloped vesicles that contained the VSV-G protein. Infectious particles were apparently generated by budding of vesicles containing VSV-G protein and the RNA replicon. These experiments reveal that an enveloped infectious agent can be much simpler than previously thought.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7954815     DOI: 10.1016/0092-8674(94)90258-5

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  64 in total

1.  Plasmid-driven formation of influenza virus-like particles.

Authors:  G Neumann; T Watanabe; Y Kawaoka
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Influenza virus matrix protein is the major driving force in virus budding.

Authors:  P Gómez-Puertas; C Albo; E Pérez-Pastrana; A Vivo; A Portela
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Measles virus structural components are enriched into lipid raft microdomains: a potential cellular location for virus assembly.

Authors:  S N Manié; S de Breyne; S Debreyne; S Vincent; D Gerlier
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  Mobilization of full-length Semliki Forest virus replicon by retrovirus particles.

Authors:  Eric Piver; Christine Collin; Noémie Renault; Thierry Bru; Jean-Christophe Pagès
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

5.  Tubulovesicular structures within vesicular stomatitis virus G protein-pseudotyped lentiviral vector preparations carry DNA and stimulate antiviral responses via Toll-like receptor 9.

Authors:  Andreas Pichlmair; Sandra S Diebold; Stephen Gschmeissner; Yasuhiro Takeuchi; Yasuhiro Ikeda; Mary K Collins; Caetano Reis e Sousa
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

6.  Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen.

Authors:  John B Schell; Nina F Rose; Kapil Bahl; Kathryn Diller; Linda Buonocore; Meredith Hunter; Preston A Marx; Ratish Gambhira; Haili Tang; David C Montefiori; Welkin E Johnson; John K Rose
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

7.  Protein transfer into human cells by VSV-G-induced nanovesicles.

Authors:  Philippe-Emmanuel Mangeot; Sandra Dollet; Mathilde Girard; Claire Ciancia; Stéphane Joly; Marc Peschanski; Vincent Lotteau
Journal:  Mol Ther       Date:  2011-07-12       Impact factor: 11.454

8.  Viral protein determinants of Lassa virus entry and release from polarized epithelial cells.

Authors:  Katrin Schlie; Anna Maisa; Fabian Freiberg; Allison Groseth; Thomas Strecker; Wolfgang Garten
Journal:  J Virol       Date:  2010-01-13       Impact factor: 5.103

Review 9.  Virus maturation by budding.

Authors:  H Garoff; R Hewson; D J Opstelten
Journal:  Microbiol Mol Biol Rev       Date:  1998-12       Impact factor: 11.056

10.  Replication and amplification of novel vesicular stomatitis virus minigenomes encoding viral structural proteins.

Authors:  E A Stillman; J K Rose; M A Whitt
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.